You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

201 Results
Blog post
In any given year, one in five Canadians will suffer from a mental health problem. For people living with cancer and their families, the risk is...
Aug 2019
Document
Document
Document
Drug
Other Name(s): Erwinase®
Jan 2020
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Dec 2019
Guidelines and Advice
Status: Current
ID: N/A
Version: 2
Jan 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - in Combination with Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia
Exceptional Access Program
    venetoclax - in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Jun 2023

Pages